Macular Degeneration is a degenerative disease manifested by the slow deterioration of the retina. Abnormal blood vessels can also form in progressed or uncommon forms of the disease. Initially the disease does not present with vision altering symptoms, however wavy and blurred vision will manifest as the disease progresses. In extremely progressed cases, patients will lose all their central vision, and can be declared legally blind.
Macular Degeneration is currently the leading cause of vision loss in the US. There are over 10 million patients living with Macular Degeneration today, more than cataracts and glaucoma cases combined. However, there is no known cure for Macular Degeneration. Anti-angiogenic eye drops can be prescribed to prevent further growth of abnormal blood vessels, but this only slows the progression of the disease. Laser and other invasive procedures can be utilized to blood vessels and scar tissue, but these procedures come with their own negative side effects and inherent risks.
Permeability to the eye is extremely low, meaning it is very difficult for substances on one side of the eye to permeate through to the other. For this reason, medications can be administered directly to the eye without risk of systemic side effects. Pyxis Biologix is currently researching compounds that would be beneficial when administered to the eye. These proprietary peptides have been shown to have anti-angiogenic properties without negative side effects. It has also been indicated that these compounds can decrease scar tissue and promote tissue regeneration, possibly resulting in regained vision.